Key facts
- This page summarizes Michael Halstead's Form 4 filing for Intra-Cellular Therapies, Inc. (ITCI).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Feb 2025, 17:31.
Michael Halstead - 31 Jan 2025 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)
- Reporting relationship
- President
- Issuer ticker
- ITCI
- Reported as of
- 31 Jan 2025
- Net transaction value
- -$722,757
- SEC form
- 4
- Accepted by SEC
- 04 Feb 2025, 17:31:30 UTC
- Prior SEC filing
- 14 Nov 2024
- Next SEC filing
- 04 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ John P. Condon, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael Halstead filed Form 4 for Intra-Cellular Therapies, Inc. (ITCI) on 04 Feb 2025.
Change
- Previous filing in this sequence was filed on 14 Nov 2024.
- Current net transaction value: -$722,757.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ITCI
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +11,017
- Change %
- Price
- $0.000000
- Shares after
- 11,017
- Date
- 31 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
ITCI
transaction
Common Stock
Tax liability
- Transaction value
- $722,757
- Shares
- -5,691
- Change %
- -52%
- Price
- $127.00
- Shares after
- 5,326
- Date
- 31 Jan 2025
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ITCI
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +45,454
- Change %
- Price
- $0.000000
- Shares after
- 45,454
- Date
- 03 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 45,454
- Exercise price
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
On March 10, 2022, the reporting person was granted performance-based restricted stock units ("PRSUs") under the Intra-Cellular Therapies, Inc. Amended and Restated 2018 Equity Incentive Plan. Each PRSU represents a contingent right to receive one share of common stock upon vesting and settlement. On January 31, 2025, 11,017 PRSUs were vested upon achievement of the reporting person's performance criteria.
Footnote F2
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the reporting person.
Footnote F3
Each restricted stock unit represents a contingent right to receive one share of common stock.
Footnote F4
On February 3, 2025, the reporting person was granted 45,454 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.